Delphine Fagegaltier

Delphine Fagegaltier is an accomplished scientist specializing in human genetics and neuroscience, currently serving as a Senior Principal Scientist at Merck since August 2022. Previously, Fagegaltier was a Staff Scientist at the New York Genome Center, leading the establishment of RNAseq production protocols for a significant ALS disease cohort. Fagegaltier’s earlier roles include work as a Scientist and Postdoctoral Research Fellow at Cold Spring Harbor Laboratory, where research focused on gene expression profiling and cancer signaling pathways, as well as a Visiting Scholar at The Ohio State University. Academic training includes a Ph.D. in Molecular and Cellular Biology from the University of Strasbourg, complemented by a Master of Science in Biochemistry and Molecular Biology.